A team of researchers from Xi'an, Shaanxi province, has outlined a new AI framework capable of diagnosing leukemia with 96.5 percent accuracy while protecting patient privacy. The study, led by Liu ...

On this week’s “Motivation with Marissa,” a local woman who has battled a series of serious health issues shares her journey.

Two U.S. Food and Drug Administration (FDA)-approved drugs for treating prostate cancer may also be effective against acute myeloid leukemia (AML), according to a new study by researchers at Penn ...

Kura Oncology has claimed FDA approval for oral menin inhibitor Komzifti for a form of acute myeloid leukaemia (AML), making ...

Ziftomenib (Komzifti) was approved on Thursday for adults with relapsed/refractory NPM1 -mutated AML who have no satisfactory ...

Leo Sproson, 16, from Bromsgrove, has been diagnosed with acute myeloid leukaemia and is in desperate need of a stem cell donor as he has no siblings and his chances of a match with a relative are ver ...

The U.S. Food and Drug Administration (FDA) has approved Komzifti (ziftomenib), which is a type of treatment known as a menin inhibitor, for use in adults with relapsed or refractory acute myeloid ...

New data show that dual-target CAR T therapy induces durable remissions in children with high-risk B-cell leukaemia, offering ...

NPM1 mutations, one of the most common genetic drivers of AML, are now actionable for patients –– Acute unmet need in R/R ...

Researchers have developed the first bioengineered human bone-marrow model to test CAR T-cell therapies for ­acute myeloid ...

Komzifti now becomes the first once-daily targeted therapy for r/r AML, though it will have to fight Syndax’s Revuforj for ...

A new type of cancer cell that "warrants urgent investigation" has been discovered in childhood leukemia and could impact ...